
Sign up to save your podcasts
Or


The FDA approval of pegcetacoplan (Syfovre, Apellis Pharmaceuticals) is a historic moment for the field of retina, finally providing a treatment option for patients with geographic atrophy. Allen C. Ho, MD, and Robert L. Avery, MD, share their initial reactions to the approval and discuss the potential effect on patient care and clinical practice.
By Retina Today4.4
1717 ratings
The FDA approval of pegcetacoplan (Syfovre, Apellis Pharmaceuticals) is a historic moment for the field of retina, finally providing a treatment option for patients with geographic atrophy. Allen C. Ho, MD, and Robert L. Avery, MD, share their initial reactions to the approval and discuss the potential effect on patient care and clinical practice.

43 Listeners

2,441 Listeners

5 Listeners

7,078 Listeners

11 Listeners

22 Listeners

52 Listeners

10 Listeners

18 Listeners

0 Listeners

1 Listeners

19 Listeners

0 Listeners

1,298 Listeners

0 Listeners